15-min delayed · Aug 26, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering Vivos Therapeutics Inc, 2 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $2.50 to $3.10, so the covering firms are broadly aligned. The average target of $2.80 sits 1000% above the current $0.25. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.25 next quarter toward $-0.82 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Strong Buy
Strong Buy00%
Buy2100%
Hold00%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to Vivos Therapeutics Inc.
As of Aug, 2 of 2 firms rate VVOS a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
VVOS EPS & revenue forecast
EPS · NEXT QUARTER
$-0.25
Range $-0.52 – $-0.07 · 4 analysts · -57% YoY
Next period, 4 analysts expect Vivos Therapeutics Inc to earn $-0.25 a share (range $-0.52 – $-0.07), versus $-0.58 a year earlier. Full-year consensus is $-1.34, growing to $-0.82 the year after.
REVENUE · NEXT QUARTER
$6.0M
Range $6.0M – $6.0M · 4 analysts · +57% YoY
Revenue is expected to reach $6.0M (range $6.0M – $6.0M), +57.4% year-over-year. Full-year consensus is $21.8M, rising to $34.1M next year.
Top analysts covering Vivos Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on VVOS.
#1
Yi Chen
HC Wainwright & Co. · Rank #276
Buy
$2.50+882.3% to target
Overall win rate
33%
+ Follow
#2
LW
Lucas Ward
Ascendiant Capital
Buy
$3.10+1118.1% to target
Coverage
—
+ Follow
#3
SH
Scott Henry
Alliance Global Partners
Buy
$6.00+2257.6% to target
Coverage
—
+ Follow
VVOS stock forecast FAQ
What is VVOS's average 12-month price target?+
The 2 analysts with a live target average $2.80 for Vivos Therapeutics Inc over the next 12 months, ranging from a $3.10 high to a $2.50 low.
Is VVOS stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 2 analyst ratings, 2 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for VVOS?+
The Street-high target is $3.10 (Ascendiant Capital), and the Street-low is $2.50 (HC Wainwright & Co.). The average of all 2 active targets is $2.80.
How many Wall Street analysts cover VVOS?+
2 analysts have an active rating on Vivos Therapeutics Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering VVOS?+
Among analysts who currently cover VVOS, Yi Chen of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #276). Their current call is Buy with a $2.50 target.
What is Vivos Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.25 per share (range $-0.52 – $-0.07) across 4 analysts. Full-year EPS is projected at $-1.34, rising to $-0.82 the following year.
How much revenue is Vivos Therapeutics Inc expected to report next quarter?+
Consensus revenue is $6.0M (range $6.0M – $6.0M). Full-year revenue is projected at $21.8M, growing to $34.1M next year.
Have analysts been upgrading or downgrading VVOS lately?+
As of Aug, 2 of 2 firms rate VVOS a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their VVOS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
